健民药业集团股份有限公司 2021 年第一季度报告 公司代码：600976 公司简称：健民集团 健民药业集团股份有限公司 2021 年第一季度报告 1 / 23 2021 年第一季度报告 健民药业集团股份有限公司 | --- | --- | |-------|----------------| | | 目录 | | í | 重要提示 . | | 二、 | 公司基本情况 . | | 11Í | 重要事项 . | | 四、 | 附录 . | 2 / 23 健民药业集团股份有限公司 2021 年第一季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人何勤、主管会计工作负责人程朝阳及会计机构负责人（会计主管人员）张英保证 季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | |--- ...

2020 年年度报告 公司代码：600976 公司简称：健民集团 健民药业集团股份有限公司 2020 年年度报告 1 / 247 2020 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准 确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责 任。 二、 公司全体董事出席董事会会议。 三、 中审众环会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报 告。 四、 公司负责人何勤、主管会计工作负责人程朝阳及会计机构负责人（会计主管人员） 张英声明：保证年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 2020 年度分配预案：以实施权益分派股权登记日登记的总股本扣减公司回购专用证券 账户中股份为基数分配利润，拟向全体股东每 10 股派发现金红利 3.66 元（含税）。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺， 敬请投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 ...

Financial Performance - Net profit attributable to shareholders of the listed company was ¥125,808,429.31, representing a significant increase of 71.25% year-on-year[17]. - Operating income for the first nine months was ¥1,606,396,781.14, a decrease of 12.32% compared to the same period last year[17]. - The weighted average return on equity increased by 3.66 percentage points to 10.01%[17]. - Basic earnings per share rose to ¥0.82, up 70.83% from ¥0.48 in the previous year[17]. - Total revenue for Q3 2020 was ¥579,073,207.10, a decrease of 19.6% compared to ¥720,222,222.12 in Q3 2019[53]. - Net profit for Q3 2020 reached ¥68,907,589.89, compared to ¥17,788,616.53 in Q3 2019, representing a significant increase[57]. - The company's total operating revenue for Q3 2020 was CNY 245,736,902.33, an increase of 13.6% compared to CNY 216,224,173.75 in Q3 2019[62]. - The net profit for Q3 2020 reached CNY 65,569,207.69, significantly up from CNY 4,774,974.25 in the same quarter last year, marking an increase of 1,272.5%[66]. - The total operating profit for Q3 2020 was ¥75,802,617.97, compared to ¥18,490,498.94 in Q3 2019, showing a substantial increase[57]. Cash Flow - The net cash flow from operating activities for the first nine months was ¥65,537,390.81, a remarkable increase of 800.75% year-on-year[17]. - The total cash inflow from operating activities for the first three quarters of 2020 was CNY 1,590,421,916.28, down from CNY 2,037,247,400.93 in the same period of 2019, a decrease of 21.9%[71]. - The total cash outflow from operating activities for the first three quarters of 2020 was CNY 1,524,884,525.47, compared to CNY 2,046,599,911.07 in the same period of 2019, a decrease of 25.4%[71]. - The net cash flow from operating activities was 128,578,571.08 RMB, compared to a negative 4,919,804.67 RMB in the same period last year, indicating a significant improvement[78]. - The total cash inflow from operating activities was 738,401,515.37 RMB, an increase from 707,404,417.16 RMB year-over-year[78]. - Cash outflow for operating activities totaled 609,822,944.29 RMB, a decrease from 712,324,221.83 RMB in the previous year[78]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥2,186,607,185.45, an increase of 13.38% compared to the end of the previous year[17]. - As of September 30, 2020, total current assets increased to approximately 1.35 billion, up from 1.17 billion in the previous year, representing a growth of about 14.9%[39]. - Total liabilities increased to approximately 885.65 million, up from 720.63 million, indicating a rise of about 22.9%[44]. - Total non-current assets increased to approximately 841.34 million from 757.84 million, reflecting a growth of about 11.0%[42]. - The total current liabilities rose to approximately 861.92 million from 698.34 million, reflecting an increase of about 23.4%[44]. - The company's cash and cash equivalents decreased to approximately 101.39 million from 144.26 million, a decline of about 29.7% year-over-year[39]. Shareholder Information - The total number of shareholders at the end of the reporting period was 8,392, with the largest shareholder holding 24.07% of the shares[23]. - The company repurchased 80,000 shares, accounting for 0.05% of total share capital, with a total expenditure of RMB 1,660,168[33]. - The company plans to repurchase shares with a total amount not less than RMB 25 million and not exceeding RMB 40 million, at a price not exceeding RMB 24 per share[33]. Investment and Income - Investment income from the associated company Wuhan Jianmin Dapeng Pharmaceutical Co., Ltd. also contributed to the profit growth[19]. - The company received government subsidies amounting to ¥2,441,963.49 during the first nine months[20]. - Investment income increased by 82.58% to RMB 86,624,031.92, mainly due to higher investment returns from associated companies[29]. - The company's investment income for Q3 2020 was CNY 27,751,836.20, compared to CNY 13,041,454.39 in Q3 2019, an increase of 112.9%[66]. - The company reported a significant increase in investment income, reaching ¥24,092,521.54 in Q3 2020 compared to ¥13,165,057.84 in Q3 2019[57]. Expenses - The company reported a significant increase in financial expenses by 201.79% to RMB 386,164.89 due to new bank loans[29]. - Other current liabilities increased by 43.06% to RMB 438,369,222.80, primarily due to increased marketing investments[29]. - Research and development expenses for Q3 2020 were ¥8,888,286.86, up from ¥6,020,951.08 in Q3 2019, indicating a 47.1% increase[53]. - The company reported a decrease in sales expenses for Q3 2020 to CNY 131,590,085.49 from CNY 152,651,778.11 in Q3 2019, a reduction of 13.8%[66].

2020 年第三季度报告 公司代码：600976 公司简称：健民集团 健民药业集团股份有限公司 2020 年第三季度报告正文 1 / 7 2020 年第三季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人何勤、主管会计工作负责人程朝阳及会计机构负责人（会计主管人员）张英保证 季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司主要财务数据和股东变化 2.1 主要财务数据 | --- | --- | --- | --- | |------------------------------------------------|------------------------------|------------------------------------|-------------------------------| | | 本报告期末 | 上年度末 | ...

证券代码：600976 证券简称：健民集团 公告编号：2020-37 健民药业集团股份有限公司 关于参加湖北辖区上市公司 2020 年度投资者网上集体 接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2020 年 8 月 26 日（星期三）14：57-16：27 会议召开方式：网络方式 一、说明会类型 根据湖北省上市公司协会《关于举办湖北辖区上市公司 2020 年度投资者网上集 体接待日活动的通知》，健民药业集团股份有限公司（以下简称"公司"）将于 2020 年 8 月 26 日下午 14:57-16:27 参加由中国证券监督管理委员会湖北监管局、湖北省 上市公司协会、深圳市全景网络有限公司联合举办的"湖北辖区上市公司 2020 年度 投资者网上集体接待日活动"，通过网络远程的方式与广大投资者沟通交流。 二、说明会召开的时间、方式 会议召开时间：2020 年 8 月 26 日（星期三）14：57-16：27； 会议召开方式：通过"全景•路演天下"（http://rs.p5w ...

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 1,027,323,574.04, a decrease of 7.61% compared to CNY 1,111,969,101.30 in the same period last year[21] - The net profit attributable to shareholders of the listed company was CNY 57,196,566.32, representing an increase of 2.22% from CNY 55,956,028.27 year-on-year[21] - The net profit after deducting non-recurring gains and losses was CNY 52,382,254.32, up 5.77% from CNY 49,526,027.66 in the previous year[21] - The net cash flow from operating activities was CNY 28,097,696.31, an increase of 43.03% compared to CNY 19,644,321.00 in the same period last year[21] - The total assets at the end of the reporting period were CNY 2,011,185,677.61, a 4.29% increase from CNY 1,928,540,639.98 at the end of the previous year[21] - The net assets attributable to shareholders of the listed company were CNY 1,227,976,387.92, reflecting a 2.21% increase from CNY 1,201,459,541.60 at the end of the previous year[21] - Basic earnings per share for the first half of 2020 were CNY 0.37, a 2.78% increase from CNY 0.36 in the same period last year[22] - The diluted earnings per share were also CNY 0.37, consistent with the basic earnings per share[22] - The weighted average return on net assets was 4.65%, a decrease of 0.20 percentage points compared to 4.85% in the previous year[22] Revenue Sources - The pharmaceutical commercial segment accounted for 50.31% of total operating revenue during the reporting period[30] - The company’s revenue from the pharmaceutical manufacturing segment is supported by a strong pipeline of new products and technologies[29] - The company’s subsidiary, specializing in traditional Chinese medicine, provides additional revenue streams through its clinic services[30] - The main product "Longmu" saw a revenue increase of 46%, while the key product "Estradiol Gel" experienced a revenue growth of 78%[47] Research and Development - The company is currently developing 16 new drug varieties, including inhalation solutions and oral solutions[29] - The company has 16 new drug varieties under research and holds a total of 73 patents, including 39 invention patents, 23 utility model patents, and 11 design patents as of June 30, 2020[46] - The company plans to increase R&D investment and accelerate new drug development to enhance competitiveness in response to industry changes[39] - Research and development expenses increased by 5.64% to approximately ¥15.6 million, reflecting the company's commitment to innovation[48] Market and Industry Trends - The overall revenue of the pharmaceutical manufacturing industry in China saw a decline of 2.3% year-on-year in the first half of 2020, totaling approximately RMB 1,109.39 billion[35] - The average price drop for products in the second batch of centralized procurement was 51.73% compared to the highest price limit, indicating a significant impact on the pharmaceutical market[39] - The pharmaceutical manufacturing sector is heavily influenced by national policies, with recent reforms increasing regulatory scrutiny, impacting future growth prospects[73] Cost Management - The company has implemented a centralized procurement model for raw materials to ensure quality and cost-effectiveness[31] - The company's operating costs decreased in line with revenue, with a year-on-year reduction of 24.24% in the pharmaceutical industry segment[53] - Sales expenses increased by 5.71% year-on-year, primarily due to increased advertising investments[53] - Management expenses decreased by 16.91% year-on-year, mainly due to the impact of government social security reduction policies[53] Environmental Responsibility - The company has established a comprehensive sewage treatment station with a daily processing capacity of 800 tons, ensuring compliance with environmental standards[104] - The company has implemented a continuous monitoring system for wastewater discharge, ensuring real-time data reporting to the environmental protection department[109] - The company has not faced any environmental law violations or administrative penalties during the reporting period[110] - The company utilizes clean energy (natural gas) in its production process, ensuring emissions comply with national air pollution standards[111] Shareholder Information - As of the reporting period, the total number of ordinary shareholders is 9,883, with the largest shareholder holding 22.07% of the shares[118] - The top ten shareholders collectively hold significant stakes, with the largest shareholder, Huali Pharmaceutical Group, owning 33,852,409 shares[118] - The company will not distribute profits or increase capital reserves for the first half of 2020, indicating a focus on reinvestment[77] Financial Position - The total current assets as of June 30, 2020, amounted to CNY 1,206,786,147.25, an increase from CNY 1,170,698,888.92 in the previous year[129] - Total liabilities reached CNY 776,478,704.83, up from CNY 720,625,499.03, representing an increase of about 7.8%[134] - Shareholders' equity totaled CNY 1,234,706,972.78, compared to CNY 1,207,915,140.95, indicating a growth of approximately 2.2%[134] - The company reported a profit distribution of -30,679,720.00, indicating a loss allocation to shareholders[182]

2020 年第一季度报告 公司代码：600976 公司简称：健民集团 健民药业集团股份有限公司 2020 年第一季度报告 1 / 21 2020 年第一季度报告 | --- | --- | --- | --- | |-------|-------|----------------|-------| | | | | | | | | | | | | | | | | | | 目录 | | | 一、 | | 重要提示 | | | 11 | | 公司基本情况 . | | | III | | 重要事项 | | | 四、 | | 附录 . | | 2 / 21 2020 年第一季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人何勤、主管会计工作负责人程朝阳及会计机构负责人（会计主管人员）张英保证 季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主 ...

Financial Performance - The company's operating revenue for 2019 was RMB 2,238,937,123.13, representing a year-on-year increase of 3.58% compared to RMB 2,161,476,637.85 in 2018[21] - The net profit attributable to shareholders of the listed company was RMB 91,490,271.53, reflecting a growth of 12.65% from RMB 81,217,735.22 in the previous year[21] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 33.49% to RMB 83,011,313.86, up from RMB 62,185,486.61 in 2018[21] - The net cash flow from operating activities was RMB 74,449,432.67, which is a 17.06% increase compared to RMB 63,598,253.15 in the previous year[21] - The total assets of the company at the end of 2019 were RMB 1,928,540,639.98, marking an 11.98% increase from RMB 1,722,182,745.84 at the end of 2018[21] - The net assets attributable to shareholders of the listed company increased by 5.41% to RMB 1,201,459,541.60 from RMB 1,139,760,504.37 in 2018[21] - The basic earnings per share for 2019 were RMB 0.60, up 13.21% from RMB 0.53 in 2018[23] - The diluted earnings per share also stood at RMB 0.60, reflecting the same growth of 13.21% compared to the previous year[23] - The weighted average return on equity increased to 7.71%, up by 0.42 percentage points from 7.29% in 2018[23] Revenue and Profit Trends - In Q3, the company's operating revenue increased to ¥720,222,222.12, while net profit attributable to shareholders decreased to ¥17,510,302.60 due to increased market investment and prior expenses from halted R&D projects[26] - In Q4, net profit attributable to shareholders further declined, primarily due to a decrease in industrial revenue and year-end impairment provisions, resulting in a net profit of ¥18,023,940.66[26] - The total operating revenue for the year was ¥2,239,936,123.12, with a net profit attributable to shareholders of ¥91,490,271.62, reflecting a year-on-year decrease[28] - Non-recurring gains and losses for 2019 amounted to ¥8,478,957.67, compared to ¥19,032,248.61 in 2018, indicating a significant reduction[30] Market and Product Development - The pharmaceutical commercial segment accounted for 50.49% of total revenue during the reporting period[35] - The company focuses on pediatric, gynecological, and geriatric treatment areas, with nearly 500 varieties of drug forms including granules, tablets, capsules, and syrups[34] - The company is developing new products such as pediatric cough syrup and heat-reducing patches, with ongoing research at its Children's Medicine Research Institute[34] - The company has implemented a centralized procurement model for raw materials, ensuring high-quality sourcing and inventory management[36] - The company is positioned to expand its market presence in economically developed regions, where sales performance is typically stronger[45] Research and Development - R&D expenses surged by 60.06% year-on-year, amounting to CNY 41.01 million, reflecting the company's increased investment in research and development[65] - The company launched four new health products and three food-medicine homologous products during the reporting period, enhancing its product portfolio[61] - The company has established four major research platforms for pediatric drug development, enhancing its R&D capabilities[117] - The company is focusing on improving existing product quality and clarifying product efficacy and safety through secondary development of old products[124] - The company has 23 ongoing research projects, including 16 new drug development projects and 1 national traditional Chinese medicine standardization project[124] Marketing and Sales Strategy - The company’s marketing strategy focused on product value, with significant efforts in advertising and brand repositioning[57] - The company employs a dual sales model for OTC products, utilizing both channel distribution and direct supply to chain pharmacies[37] - The company is enhancing its marketing strategies and digital management to boost sales across hospitals, chains, and pharmacies[159] Social Responsibility - The company has been actively involved in social responsibility initiatives, including educational support for underprivileged students[196] - The company donated a total of 2.447 million RMB to support 325 students, including 20 students from Hanyang District in 2019[198] - The company allocated 600,000 RMB for poverty alleviation initiatives, specifically aiding 20 impoverished students[199] - The company emphasizes its commitment to social responsibility and sustainable development, as detailed in its 2019 Social Responsibility Report[200] Financial Management - The company has implemented a cash dividend policy since 2008, distributing a total of RMB 420 million over 11 consecutive years[167] - For the fiscal year 2019, the board proposed a cash dividend of RMB 2.00 per 10 shares, totaling RMB 30,679,720, with a remaining undistributed profit of RMB 446,115,053.13[167] - The cash dividend for 2019 represents 33.53% of the net profit attributable to ordinary shareholders, compared to 37.77% in 2018[168] - The company has revised its profit distribution policy to enhance transparency and protect investor interests, approved by the shareholders' meeting[166]

2019 年第三季度报告 公司代码：600976 公司简称：健民集团 健民药业集团股份有限公司 2019 年第三季度报告 1 / 28 2019 年第三季度报告 一、 重要提示 二、 公司基本情况. 11[ 重要事项 四、 附录 目录 2 / 28 2019 年第三季度报告 2.1 主要财务数据 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人何勤、主管会计工作负责人程朝阳及会计机构负责人（会计主管人员）张英保证 季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 | --- | --- | --- | --- | |-------------------------------------------------|----------------------------|----------------------------------|----- ...

Financial Performance - The company's operating revenue for the first half of 2019 was CNY 1,111,969,101.30, representing a 3.48% increase compared to CNY 1,074,606,863.07 in the same period last year[24]. - The net profit attributable to shareholders of the listed company was CNY 55,956,028.27, a decrease of 2.67% from CNY 57,492,500.88 in the previous year[24]. - Basic earnings per share for the first half of 2019 were CNY 0.36, down 5.26% from CNY 0.38 in the same period last year[25]. - The weighted average return on net assets was 4.85%, a decrease of 0.36 percentage points compared to the previous year[27]. - The company reported a non-recurring gain of 6,430,000.61 RMB, with a government subsidy contributing 1,306,017.77 RMB and a gain from entrusted investment management of 7,234,972.20 RMB[30]. - The company’s operating revenue increased by 3.48% year-on-year to ¥1,111,969,101.30, with pharmaceutical industrial revenue growing by 10.48% and pharmaceutical commercial revenue decreasing by 3.34%[63]. - The net profit attributable to shareholders was 5,595.60 million RMB, reflecting a decline of 2.67% compared to the previous year[56]. - The net profit for the first half of 2019 was ¥59,168,635.60, down from ¥63,949,083.84 in the same period of 2018, indicating a decline of about 7.5%[175]. Cash Flow and Investments - The net cash flow from operating activities decreased by 53.86% to CNY 19,644,321.00, primarily due to longer collection cycles from pharmaceutical clients[24]. - Net cash flow from investing activities increased by 136.81% to ¥36,590,311.37, mainly due to partial redemption of financial products[63]. - Cash flow from operating activities was approximately ¥1.22 billion, a slight decrease from ¥1.23 billion in the first half of 2018[189]. - Investment cash inflow amounted to CNY 1,064,792,988.75, an increase from CNY 800,485,000.00 year-over-year[194]. - The ending cash and cash equivalents balance was CNY 108,445,004.85, compared to CNY 144,145,677.91 at the end of the previous period[194]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,777,304,948.34, an increase of 3.20% from CNY 1,722,182,745.84 at the end of the previous year[24]. - The total current assets as of June 30, 2019, amounted to RMB 1,135,227,145.37, an increase from RMB 1,097,868,552.27 as of December 31, 2018, reflecting a growth of approximately 3.7%[156]. - Total liabilities reached ¥605,108,377.03, up from ¥577,109,926.02, marking an increase of around 4.9%[162]. - The company's total equity reached ¥1,098,145,126.73, up from ¥1,092,806,728.17, showing a slight increase of approximately 0.5%[172]. Market and Industry Trends - The pharmaceutical manufacturing industry saw a total revenue of 12,227.50 billion RMB in the first half of 2019, representing a year-on-year growth of 4.9%[42]. - The profit total for the pharmaceutical manufacturing sector was 160.82 billion RMB, with a profit margin of 13.15%, indicating a year-on-year profit growth of 9.4%[42]. - The company aims to adapt to changes in the pharmaceutical industry environment and regulatory landscape to ensure stable business development[46]. - Increased competition in the pharmaceutical industry due to policy changes and mergers poses significant market risks[94]. Research and Development - The company plans to continue focusing on research and development, as well as market expansion strategies[8]. - R&D expenses increased by 41.15% to ¥14,798,178.68, reflecting a significant investment in R&D projects[63]. - The company is actively developing pediatric formulations and has made progress in secondary development projects, with several standards and technical specifications established[58]. - The company holds 55 patents, including 31 invention patents, 12 utility model patents, and 12 design patents[53]. Social Responsibility and Environmental Compliance - The company donated 1 million RMB to the China Population Welfare Foundation for the Women and Children Care Fund in July 2019[121]. - The company has committed to social responsibility by focusing on education and health initiatives for women and children[116]. - The company’s subsidiary, Yekaitai Pharmaceutical, meets environmental discharge standards for wastewater and air pollutants[122]. - The company operates a comprehensive sewage treatment plant with a daily processing capacity of 800 tons, ensuring compliance with discharge standards[129].